NEW YORK, July 29, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Illumina, Inc. (NASDAQ: ILMN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Exelixis, Inc. (NASDAQ: EXEL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5214-100free.
--
Illumina, Inc. Research Reports
On July 23, 2014, Illumina, Inc. (Illumina) reported Q2 FY 2014 financial results (period ended June 29, 2014). In Q2 FY 2014, the Company recorded revenue of $447.6 million, up 29.3% YoY. Q2 FY 2014 net income was $46.6 million, or $0.31 per diluted share, compared to $35.9 million, or $0.26 per diluted share, in Q2 FY 2013. Based on strong first half results, Illumina has revised its full-year 2014 guidance with revenue expected to increase 25% to 26%. "We are witnessing tremendous interest in our products, which led to record financial results in the second quarter," stated Jay Flatley, CEO of Illumina. "With the most extensive sequencing portfolio available, we remain extremely well-positioned to develop and address the large and untapped market opportunities ahead of us." The full research reports on Illumina are available to download free of charge at:
http://www.analystsreview.com/Jul-29-2014/ILMN/report.pdf
--
Alexion Pharmaceuticals, Inc. Research Reports
On July 24, 2014, Alexion Pharmaceuticals, Inc. (Alexion) reported Q2 2014 financial results. In Q2 2014, the Company's net product sales increased 38.5% YoY to $512.5 million. Q2 2014 net income was $166.5 million, or $0.83 per diluted share, compared to $95.9 million, or $0.48 per diluted share, in Q2 2013. "In the second quarter of 2014, we served an increasing number of new patients with PNH and aHUS worldwide while simultaneously reaching several significant milestones across our pipeline, including the filing of our MAA for asfotase alfa for HPP in Europe, which has been accepted and granted accelerated assessment," said Leonard Bell, M.D., CEO of Alexion. "During the quarter we also continued to execute on key initiatives to further improve operational and financial efficiencies across our global operations." The Company revised its full-year 2014 revenue guidance range to $2.18 to $2.20 billion. The full research reportson Alexion are available to download free of charge at:
http://www.analystsreview.com/Jul-29-2014/ALXN/report.pdf
--
Questcor Pharmaceuticals, Inc. Research Reports
On July 24, 2014, Questcor Pharmaceuticals, Inc. (Questcor) reported Q2 2014 financial results. In Q2 2014, the Company's net sales were $278.8 million, up 51.1% YoY. Q2 2014 net income was $96.4 million, or $1.54 per diluted share, compared with $69.1 million, or $1.12 per diluted share, in Q2 2013. The Company also reported that it shipped 8,850 vials of Acthar during Q2 2014, setting a new record for Acthar shipments in a quarter, representing an increase of 26% YoY. Don M. Bailey, President and CEO, said, "Similar to 2013, Acthar prescription activity picked up significantly in the second quarter, led by growth in our rheumatology indications and a resurgence in prescriptions for nephrotic syndrome. In addition, BioVectra experienced significantly improved results and we are in the process of expanding BioVectra's specialty fermentation capacity in order to meet the growing demand for their contract manufacturing services." The full research reports on Questcor are available to download free of charge at:
http://www.analystsreview.com/Jul-29-2014/QCOR/report.pdf
--
Jazz Pharmaceuticals plc Research Reports
On July 22, 2014, Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) announced that it will release its Q2 2014 financial results on August 5, 2014, after the close of the financial markets. On the same day, the Company has scheduled a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss the results and to provide a business and financial update. The full research reports on Jazz Pharmaceuticals are available to download free of charge at:
http://www.analystsreview.com/Jul-29-2014/JAZZ/report.pdf
--
Exelixis, Inc. Research Reports
On July 16, 2014, Exelixis, Inc. (Exelixis) announced that it will release its Q2 2014 financial results on July 31, 2014, after the markets close. On the same day, the Company has scheduled a conference call at 5:00 p.m. EDT / 2:00 p.m. PDT to discuss the results and provide general business update. The full research reports on Exelixis are available to download free of charge at:
http://www.analystsreview.com/Jul-29-2014/EXEL/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
